Jefferies assumes coverage on Cellectis stock with Buy rating

Financial analysts at Jefferies initiated coverage on biotechnology company Cellectis stock with a Buy rating in recent market activity, expressing confidence in the company's pipeline and growth potential. This development comes as Jefferies joins other investment firms in evaluating Cellectis' position within the competitive gene-editing sector. The Buy rating suggests that Jefferies analysts believe Cellectis' shares will outperform the market over the coming months, potentially driven by the company's innovative approaches in CAR-T cell therapies and gene editing technologies. Cellectis has been developing novel treatments for various cancers and genetic disorders, positioning itself as a key player in the rapidly evolving biotechnology landscape. The endorsement from a prominent financial institution like Jefferies typically leads to increased visibility and trading activity for the covered company, potentially boosting its market valuation and attracting new investors to the stock.